drugset / Trial / NCT01205867

Study to Investigate the Safety and Tolerability of AZD8848 in Butyrylcholinesterase Deficient Subjects

NCT01205867 ↗

Phase 1 Completed 22 enrolled AstraZeneca
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the safety and tolerability of AZD8848 in Butyrylcholinesterase deficient subjects in comparison with sex and age matched control subjects.

Timeline

Start
2010-09
Primary completion
2011-02
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD8848 Small molecule — Intranasal